Durvalumab + Gemcitabine + Cisplatin
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Biliary Tract Cancers (BTC)
Conditions
Biliary Tract Cancers (BTC)
Trial Timeline
Oct 21, 2024 → Mar 30, 2027
NCT ID
NCT06611345About Durvalumab + Gemcitabine + Cisplatin
Durvalumab + Gemcitabine + Cisplatin is a pre-clinical stage product being developed by AstraZeneca for Biliary Tract Cancers (BTC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06611345. Target conditions include Biliary Tract Cancers (BTC).
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06858735 | Phase 2 | Recruiting |
| NCT06611345 | Pre-clinical | Recruiting |
Competing Products
20 competing products in Biliary Tract Cancers (BTC)